Clinical Trials Browser

Interventional × Gastrinoma × NET × Clear all

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

Phase 2/3 Terminated

36 enrolled 14 charts

EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT04915144 2023-02-21

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Phase 2 Withdrawn

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Vipoma, Insulinoma, Gastrinoma, Neuroendocrine Tumors

NCT00050349 2017-03-01

EPO906 in Carcinoid and Other Neuroendocrine Tumors

Phase 2 Completed

33 enrolled

EndocrineNET

Carcinoid Tumor, Carcinoma, Vipoma, Neoplasm Metastasis, Neoplasms, Gastrinoma, Neuroendocrine Tumors

NCT00869050 2016-07-25

Capecitabine and Temozolomide for Neuroendocrine Cancers

Phase 2 Completed

41 enrolled 9 charts

EndocrineGastrointestinalNET

Carcinoid Tumor, Vipoma, Pancreatic Neoplasms, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Gastrinoma, Carcinoma, Medullary, Neuroendocrine Tumors

NCT00131911 2014-11-17

Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

Phase 2 Completed

93 enrolled 10 charts

EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Clinical Trials

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

EPO906 in Carcinoid and Other Neuroendocrine Tumors

Capecitabine and Temozolomide for Neuroendocrine Cancers

Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors